Drug discovery in the metabolic syndrome: Context and some recent developments

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 6, 2007, Pages 801-808

  Suckling, Keith ^a  

^a NONE   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase; AMP activated protein kinase; Animal model; Atherosclerosis; Dyslipidaemia; Insulin resistance; Nuclear hormone receptor; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; ATM PROTEIN; CARBENOXOLONE; CHLOROQUINE; ENZYME INHIBITOR; FARNESOID X RECEPTOR; FATTY ACID BINDING PROTEIN; FIBRIC ACID DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; LIVER X RECEPTOR; LIVER X RECEPTOR BLOCKING AGENT; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CONFOUNDING VARIABLE; DNA MODIFICATION; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY LIVER; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC ANALYSIS; GLUCOSE TOLERANCE; HIGH THROUGHPUT SCREENING; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X;

EID: 34250217741     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.6.801     Document Type: Review

References (68)

1. GRUNDY SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. (2006) 47:1093-1100.
2. DESPRES JP, LEMIEUX I: Abdominal obesity and metabolic syndrome. Nature (2006) 444:881-887.
3. SATTAR N: The metabolic syndrome: should current criteria influence clinical practice? Curr. Opin. Lipidol. (2006) 17:404-411.
4. GERSTEIN HC, YUSUF S, BOSCH J et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 368:1096-1015.
5. CAMPBELL IW: The clinical significance of PPARγ agonism. Curr. Mol. Med. (2005) 5:349-363.
6. 1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Investig. Drugs (2006) 15:307-315.
7. SCHEEN AJ, FINER N, HOLLANDER P et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet (2007) 368:1660-1672.
8. LINDSTROM J, ILANNE-PARIKKA P, PELTONEN M et al.: Sustained reduction in the incidence of Type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet (2006) 368:1673-1679.
9. MILLER ER, III, ERLINGER TP, APPEL LJ: The effects of macronutrients on blood pressure and lipids: an overview of the DASH and OmniHeart trials. Curr. Atheroscler. Rep. (2006) 8:460-465.
10. KARAGIANNIS A, MIKHAILIDIS DP, ATHYROS VG et al.: The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin. Ther. Targets (2007) 11:191-205.
11. COOKE D, BLOOM S: The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat. Rev. Drug Discov. (2006) 5:919-931.
12. SATTAR N, WILLIAMS K, SNIDERMAN AD et al.: Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation (2004) 110:2687-2693.
13. KAHN SE, HULL RL, UTZSCHNEIDER KM: Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature (2006) 444:840-846.
14. BARRETT PH, CHAN DC, WATTS GF: Design and analysis of lipoprotein tracer kinetics studies in humans. J. Lipid Res. (2006) 47:1607-1619.
15. LAU DCW, DHILLON B, YAN HY et al.: Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol Heart Circulat. Physiol. (2005) 288:H2031-H2041.
16. MURPHY KG, BLOOM SR: Gut hormones and the regulation of energy homeostasis. Nature (2006) 444:854-859.
17. HOTAMISLIGIL GS: Inflammation and metabolic disorders. Nature (2006) 444:860-867.
18. HAN SH, QUON MJ, KOH KK: Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr. Opin. Lipidol. (2007) 18:58-65.
19. ALESSI MC, JUHAN-VAGUE I: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. (2006) 26:2200-2207.
20. HARTVIGSEN K, BINDER CJ, HANSEN LF et al.: A diet-induced hypercholesterolemic routine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. (2007) 27:878.
21. SUCKLING KE: The ideal model in atherosclerosis and dyslipidaemia - does it exist? Expert Opin. Drug Discov. (2007) 1:507-511.
22. AKIYAMA TE, LAMBERT G, NICOL CJ et al.: Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a Western diet. J. Biol. Chem. (2004) 279:20874-20881.
23. HIRAOKA-YAMAMOTO J, NARA Y, YASUI N et al: Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin. Exp. Pharmacol. Physiol. (2004) 31:107-109.
24. VINE DF, TAKECHI R, RUSSELL JC et al.: Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:-LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis (2007) 190:282-290.
25. UENO T, TREMBLAY J, KUNES J et al.: Rat model of familial combined hyperlipidemia as a result of comparative mapping. Physiol. Genomics (2004) 17:38-47.
26. DRAKE TA, SCHADT EE, DAVIS RC et al.: Integrating genetic and gene expression data to study the metabolic syndrome and diabetes in mice. Am. J. Ther. (2005) 12:503-511.
27. SHMULEWITZ D, HEATH SC, BLUNDELL ML et al.: Linkage analysis of quantitative traits for obesity, diabetes, hypertension, and dyslipidemia on the island of Kosrae, Federated States of Micronesia. Proc. Natl. Acad Sci. USA (2006) 103:3502-3509.
28. MORAND JPF, MACRI J, ADELI K: Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. J. Biol. Chem. (2005) 280:17626-17633.
29. GAEMERS IC, GROEN AK: New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol. (2006) 17:268-273.
30. DEN BOER M, VOSHOL PJ, KUIPERS F et al.: Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. (2004) 24:644-649.
31. LEUNG N, NAPLES M, UFFELMAN K et al.: Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance. Atherosclerosis (2004) 174:235-241.
32. CHAPMAN MJ: Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. (2006) 111:893-908.
33. KAWAI T, ITO T. OHWADA K, MERA Y et al.: Hereditary postprandial hypertriglyceridemic rabbit exhibits insulin resistance and central obesity: a novel model of metabolic syndrome. Arterioscler. Thromb. Vasc, Biol. (2006) 26:2752-2757.
34. ARDERN HA, BENSON GM, SUCKLING KE et al.: Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit. J. Lipid Res. (1999) 40:2234-2243.
35. DE ROOS B, CASLAKE MJ, ARDERN HA et al.: Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia. Atherosclerosis (2001) 156:249-254.
36. WAGNER JE, KAVANAGH K, WARD GM et al.: Old world nonhuman primate models of Type 2 diabetes mellitus. ILAR J. (2006) 47:259-271.
37. BODKIN NL, PILL J, MEYER K, HANSEN BC: The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Hormone Metab. Res. (2003) 35:617-624.
38. WINEGAR DA, BROWN PJ, WILKISON WO et al.: Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J. Lipid Res. (2001) 42:1543-1551.
39. OLIVER WR, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98:5306-5311.
40. GALILI O, VERSARI D, SATTLER KJ et al.: Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am. J. Physiol. Heart Circ. Physiol (2007) 292:H904-H911.
41. DRUCKER D, EASLEY C, KIRKPATRICK P: Sitagliptin. Nat. Rev. Drug Discov. (2007) 6:109-110.
42. GERVOIS P, FRUCHART J-C, STAELS B: Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Prac. Endocrinol. Metab. (2007) 3:145-156.
43. SPRECHER DL, MASSIEN C, PEARCE G et al.: Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler. Thromb. Vasc. Biol. (2007) 27:359-365.
44. FURNSINN C, WILLSON TM, BRUNMAIR B: Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia (2007) 50:8-17.
45. -/- mice. Atherosclerosis (2005) 181:29-37.
46. VOSPER H, PATEL L, GRAHAM TL et al.: The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J. Biol. Chem. (2001) 276:44258-44265.
47. WANG D, WANG H, GUO Y et al.: Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. USA (2006) 103:19069-19074.
48. FYFFE SA, ALPHEY MS, BUETOW L et al.: Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids. J. Mol. Biol. (2006) 356:1005-1013.
49. LEE FY, LEE H, HUBBERT ML et al.: FXR, a multipurpose nuclear receptor. Trends. Biochem. Sci. (2006) 31:572-580.
50. GEYEREGGER R, ZEYDA M, STULNIG TM: Liver X receptors in cardiovascular and metabolic disease. Cell Mol. Life Sci. (2006) 63:524-539.
51. MITRO N, MAK PA, VARGAS L et al.: The nuclear receptor LXR is a glucose sensor. Nature (2007) 445:219-223.
52. WANG M: Inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 for the treatment of metabolic syndrome. Curr. Opin. Investig. Drugs (2006) 7:319-323.
53. STULNIG TM, OPPERMANN U, STEFFENSEN KR et al.: Liver X receptors downregulate 11β-hydroxysteroid dehydrogenase Type 1 expression and activity. Diabetes (2002) 51:2426-2433.
54. TOMLINSON JW, SHERLOCK M, HUGHES B et al.: Inhibition of 11β-HSD1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J. Clin. Endocrinol. Metab. (2007) In Press.
55. HERMANOWSKI-VOSATKA A, BALKOVEC JM, CHENG K et al.: 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. (2005) 202:517-527.
56. LONG YC, ZIERATH JR. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. (2006) 116:1776-1783.
57. YOON MJ, LEE GY, CHUNG JJ et al.: Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α. Diabetes (2006) 55:2562-2570.
58. GUARENTE L: Sirtuins as potential targets for metabolic syndrome. Nature (2006) 444:868-874.
59. YU X, MCCORKLE S, WANG M et al.: Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia (2004) 47:2012-2021.
60. ZANG M, XU S,MAITLAND-TOOLAN KA et al.: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes (2006) 55:2180-2191.
61. BRUSQ JM, ANCELLIN N, GRONDIN P et al.: Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. (2006) 47:1281-1288.
62. SHAW RJ, LAMIA KA, VASQUEZ D et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 310:1642-1646.
63. ZANG MW, ZUCCOLLO A, HOU XY et al.: AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. (2004) 279:47898-47905.
64. SCHEUERMANN-FREESTONE M, MADSEN PL, MANNERS D et al.: Abnormal cardiac and skeletal muscle energy metabolism in patients with Type 2 diabetes. Circulation (2003) 107:3040-3046.
65. SCHNEIDER JG, FINCK BN, REN J et al.: ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. (2006) 4:377-389.
66. BOORD JB, FAZIO S, LINTON MF: Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol, (2002) 13:141-147.
67. MAEDA K, CAO HM, KONO K et al.: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. (2005) 1:107-119.
68. BOORD JB, MAEDA K, MAKOWSKI L et al.: Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation (2004) 110:1492-1498.